Predictive values of IGRAs and TST for progression to active disease in TB. 3 rd Global IGRA Symposium January 2012.
|
|
- Liliana Barton
- 6 years ago
- Views:
Transcription
1 Predictive values of IGRAs and for progression to active disease in TB contacts in Singapore Cynthia B E Chee 1, K W KhinMar 1, S H Gan 1, J Cutter, T M Barkham, Y T Wang 1 1 TB Control Unit, Tan Tock Seng Hospital, Singapore Communicable Disease Division, Ministry of Health, Singapore Dept of Laboratory Medicine, Tan Tock Seng Hospital, Singapore rd Global IGRA Symposium 1-15 January 1 Background Singapore: an intermediate TB incidence country Since 195s : universal BCG-vaccination at birth 195s - 1 : BCG re-vaccination policy for school leavers (at 1 or 16 years of age) : Stagnation of TB rate at 5-55 /1, population (citizens/permanent residents) 1998: National TB Programme implemented targeted screening of close contacts for preventive therapy () 4: Availability of commercial IGRAs
2 Two cohorts of adult non-hiv contacts tested with an IGRA and (TU RT PPD) 961 community contacts (household, workplace) Screened with T-SPOT.TB and from January-September 5; Decision for based on T-SPOT result in the majority regimen: Isoniazid for 6 months, self-administered 11 contacts in congregate settings (prisons, nursing homes, mental institute) Screened with QuantiFERON Gold In-tube (QFT-IT) and from November 5-May 7 Decision for based on QFT result regimen: Isoniazid for 9 months, directly-observed Of eligible contacts, 81% in T-SPOT cohort; 85% in QFT cohort commenced Completion rate : 77% for T-SPOT cohort; 89% for QFT cohort Follow-up: commenced on were followed 4-6 weekly until treatment completion, then discharged QFT +ve contacts in congregate settings who could not take were reviewed 6 monthly for years Test-positive community contacts who did not take were discharged with advice Test-negative contacts were discharged matched with National TB Notification Registry for notification of active TB as at July (6 in T-SPOT group, 1 in QFT group) One case with known re-exposure to active TB excluded (T-SPOT group)
3 screened with T-SPOT and Flow-chart according to T-SPOT 961 of 99 T-SPOT +ve # 98 (44%) T-SPOT ve 55 (56%) 64 No * % 6 active TB 1 failed T-SPOT 51 without either test result # >= 6 SFCs /5, PBMCs No * 477 * Includes non-completers 99.6% screened with T-SPOT and Flow-chart according to (1 mm cut-off) 961 of 99 >= 1 mm 77 (8%) < 1 mm 166 (18%) 8 No * % 6 active TB 1 failed T-SPOT 51 without or T-SPOT results No * 157 * Includes non-completers 1%
4 Number screened with both tests N=9 Treatment status No. who developed active TB / No. screened Person-years Incidence / 1 PYs T-SPOT-/- / N=141 (15.6%) No / T-SPOT-/+ / N=64 (4.%) No /7 (.9%) T-SPOT+/- / N=5 (.8%) No / T-SPOT+/+ /56 (.8%) N=7 (41.%) No 1/117 (.9%) positivity cutoff >=1 mm screened with QFT-IT and Flow-chart according to QFT 11 of 7 QFT +ve 75 (5%) QFT ve 814 (75%) 191 No * 84.% 1 Active 1 Indeterminate QFT 8 No No % * includes non-completers
5 screened with QFT-IT and Flow-chart according to (1 mm cut-off) 11 of 7 >= 1mm 645 (59%) < 1 mm 444 (41%) 155 No * Active 1 Indeterminate QFT 8 No No * 48 * Includes non-completers 99. Number screened with both tests N=189 Treatment status No. who developed active TB / No. screened QFT-/- / Personyears Incidence / 1 PYs N=97 (6.5%) No /97 (.8%) QFT-/+ / N=417 (8.%) No 4/417 (1.%) QFT+/- / N=47 (4.%) No /11.6 QFT+/+ /155 (1.9%) N=8 (.9%) No /7 (.7%).4 8. positivity cutoff >=1 mm
6 Limitations Majority of IGRA-positive subjects received LTBI treatment Possible selection bias for those who did not receive Rx (more HH than non-hh contacts received in T-SPOT group) No DNA fingerprinting data of contact and source MTC isolates Unable to rule out possibility of infection during follow-up period (5 developed active TB > 6 months after screening) No systematic follow-up of all contacts Drop out rate (eg. death, left country) uncertain Summary of findings of T-SPOT.TB :.7% (vs.7%) of T-SPOT.TB : 99.6% (vs 1%) T-SPOT+/+ contacts have RR of [95% CI ] of developing active TB vs those T-SPOT- /+ of QFT-IT :.% (vs 1.%) of QFT-IT : 99.1% (vs 99.%) QFT+/+ contacts have RR of 4.1 [95% CI.77-.] of developing active TB vs those QFT-/+; and RR of [95% CI ] of developing active TB vs those QFT-/-
7 Conclusions For TB contacts in Singapore s intermediate burden setting: Both T-SPOT and QFT-IT, and had low Consistent with meta-analysis by Rengaka et al. Lancet 1;1:45-55 All three tests had high In our population, use of IGRA will reduce number considered for Acknowledgements Nursing Officer Kwee-Yin Han, Senior Staff Nurses Pushparani and Chwee-Kim Koh & Staff of TB Control Unit Contact Clinic Mr Chua Sock Kiang and Staff, Singapore Prisons Service Dr Shen Liang, Yong Loo Lin School of Medicine, National University of Singapore Oxford Immunotec for providing T-SPOT.TB kits at a reduced price for this project Ministry of Health, Singapore
TB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationMonitoring & evaluation LTBI management in the Netherlands. Key lessons.
Monitoring & evaluation LTBI management in the Netherlands. Key lessons. Gerard de Vries, MD MSc PhD, Coordinator TB control the Netherlands, KNCV Tuberculosis Foundation/RIVM-CIb Global WHO Consultation
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationWhat Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ
What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ Outline Combination prevention for HIV Approaches to TB prevention Individual Household/key
More informationRevised Technical Instructions for Civil Surgeons. October 9, 2018
Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationComparison of Sensitivities of Two Commercial Gamma Interferon Release Assays for Pulmonary Tuberculosis
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 1935 1940 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.02403-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Comparison
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationLTBI monitoring and evaluation in the Netherlands
LTBI monitoring and evaluation in the Netherlands 17 th Wolfheze Workshops 2015, Den Haag Connie Erkens MD MPH Senior TB consultant Content presentation Epidemiology Target groups for programmatic LTBI
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationNo, not these...or these.
Interpretation of IGRA Results - Session Commentary - Matthew J. Binnicker, Ph.D., D(ABMM) The Big Three: No, not these...or these. The Big Three: Commonly asked questions when interpreting IGRA results:
More informationProgrammatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.
Programmatic management of latent TB infection: Global perspective and updates Haileyesus Getahun, MD, MPH, PhD. What is latent TB infection? A state of persistent immune response to stimulation by Mycobacterium
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationScreening and management of latent TB Infection Gerry Davies
Screening and management of latent TB Infection Gerry Davies Reader in Infection Pharmacology Institutes of Infection and Global Health & Translational Medicine HIV Scientific Meeting Liverpool 21st July
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey Department of Health,? NO. The TB-57 form is completed by the school nurse and kept on-site
More informationTB prevention studies in PLHIV: recent updates and what can they tell us for the future?
TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working
More informationUtility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children
Clinical Therapeutics/Volume 34, Number 5, 2012 Utility of Interferon- Release Assay Results to Monitor Anti- Tubercular Treatment in Adults and Children Elena Chiappini, MD, PhD, Francesca Fossi, MD,
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationDiagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011 Douglas Hornick, MD has the following disclosures to
More informationModeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre
Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Overview The problem Treating active TB does not seem to be enough The solution:
More information결핵노출접촉자감염관리 서울아산병원감염내과 김성한
결핵노출접촉자감염관리 서울아산병원감염내과 김성한 TB incidence (2012) TB incidence South Korea 108 China 73 Taiwan 68 Portucal 26 Japan 19 Spain 14 US 3.6 * unit- per 100,000 population Adapted from WHO Adapted from WHO Emerg
More informationNIHR HTA Programme. 09 July 2013
NIHR HTA Programme 09 July 2013 The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton, manages evaluation research programmes and activities for the
More informationQuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
Jpn. J. Infect. Dis., 70, 502 506, 2017 Original Article QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients Thana Khawcharoenporn 1 *, Benjawan Phetsuksiri 2, Janisara
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationInterferon-gamma release assay for treatment monitoring of active tuberculosis
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationTB Intensive. San San Antonio, Texas. December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD; Mayo Clinic December 1, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More informationDirector, University Health Services. Medical Director
March 2011 Issued, Revised, or Reviewed) Approved by: Office of Student Affairs Director, University Health Services Medical Director SUBJECT: SCREENING OF HEALTH SERVICES STAFF FOR TUBERCULOSIS POLICY
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationAT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationTuberculosis Infection in the US Military
Tuberculosis Infection in the US Military Edward Munch. The Sick Child. (1885) Anjali Kunz, MAJ (P), MC Pediatric Infectious Disease, Chief, JBLM Courtesy of : Paul B. Keiser, Feb 2014 Walter Reed Army
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More information